Back to News
Market Impact: 0.3
Myriad Genetics Raises FY26 Revenue Outlook Midpoint; Agrees To Sell Prenatal Health Business
Source: Nasdaq
Corporate EarningsCorporate Guidance & OutlookCompany Fundamentals
Myriad Genetics reported that Q3 2026 revenue increased sequentially but declined slightly year over year. The company modestly raised the midpoint of its full-year revenue guidance and announced an agreement, but the available article text does not specify its terms or provide revenue figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
MYGN0.40
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise